Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

Abstract 4135869: Local Ethanol Infusion after Pulsed Field Ablation Enhances Acute Efficacy of In Vivo Ventricular Electroporation
Otsuka, Naoto , Tri, Jason , ying, yang , Nguyen, Duy T. , Koya, Taro , Sauer, William H. , Asirvatham, Samuel J.

Mayo Clinic

Circulation | November 13, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4135869 Get It

Background: Pulsed field ablation (PFA) has emerged as an innovative technology for treating cardiac arrhythmias. PFA increases cell permeability, which can lead to apoptosis. Greater PFA energy may be necessary to ablate ventricular myocardium for ventricular tachycardia circuits, but this carries risks of side effects such as gaseous formation (microbubbles) and hemolysis. Ethanol (EtOH) infusion has been used to ablate pathologic myocardial tissues in hypertrophic cardiomyopathy and for refractory arrhythmias. Hypothesis: We hypothesize that PFA in the ventricle can increase EtOH uptake through PFA-generated pores, thereby enhancing ablation efficacy, even at low powers, by utilizing the cell permeability effects of PFA. Aim: The aim of this study is to investigate the effect of local EtOH infusion after PFA on lesion size in porcine ventricles. Methods: The ventricles of five porcine subjects were ablated in vivo with a PFA low power setting (750 V, at 20 μs for 50 pulses separated by 200 ms) using a focal bipolar irrigated ablation catheter and BTX 830 electroporation generator (Harvard Apparatus). After PFA was performed, 2 ml of 90 % EtOH vs. saline (control) was infused through the catheter tip to the site of ablation. We compared the electrograms voltage amplitude reduction before and after PFA, and the ablation lesion characteristics. Results: A total of 10 lesions in the control group and 9 lesions in the EtOH group were analyzed. For the controls, the voltage after PFA was not reduced. In contrast, for the EtOH group, the voltage after PFA was significantly reduced ( Figure 1A ). On gross pathology, there were significant differences in ablation lesion depths and volumes between the 2 lesion sets ( Figure 1A-B ). Conclusion: Local EtOH infusion after ventricular PFA enhanced acute efficacy of electroporation. Concurrent PFA with local EtOH infusion has the potential to improve efficacy without requiring higher energy parameters, thereby reducing PFA risks. Future studies on chronic efficacy are warranted.
Large‐scale deep proteomic analysis in Alzheimer's disease brain regions across race and ethnicity
Fox, Edward J., Liu, Yue , Dammer, Eric B. , Modeste, Erica , Duong, Duc M. , Yin, Luming, Trautwig, Adam N., Guo, Qi , Xu, Kaiming , Ping, Lingyan, Reddy, Joseph S. , Allen, Mariet , Quicksall, Zachary , Heath, Laura , Scanlan, Jo, Wang, Minghui , Linden, Abby Vander , Poehlman, William L. , Chen, Xianfeng , Baheti, Saurabh , Ho, Charlotte C.G. , Nguyen, Thuy , Yepez, Geovanna, Mitchell, Adriana O., Oatman, Stephanie R., Wang, Xue , Carrasquillo, Minerva M. , Runnels, Alexi , Golde, Todd E. , Zhang, Bin , Haroutunian, V., Gearing, Marla , Lah, James J., Jager, Philip L. De , Bennett, David A., Ertekin‐Taner, Nilüfer , Wingo, Aliza P. , Wingo, Thomas S. , Seyfried, Nicholas T. , Bennett, David A. , Bennett, David A. , Ho, Charlotte, Dammer, Eric B , Wingo, Thomas S , Seifar, Fatemeh , Shantaraman, Anantharaman , Ping, Lingyan, Wang, Erming , Carrasquillo, Minerva M. , Beach, Thomas, Serrano, Geidy E. , Dickson, Dennis W. , Lee, Edward B. , Prokop, Stefan , Barnes, Lisa L. , Greenwood, Anna, Levey, Allan I.

Mayo Clinic

Alzheimer's & Dementia | November 13, 2024 | Volume: 20 | Issue: 12 | Pages: 8878-8897

10.1002/alz.14360 | PMID 39535480 Get It

Abstract INTRODUCTION Alzheimer's disease (AD) is the most prevalent neurodegenerative disease, yet our comprehension predominantly relies on studies within non‐Hispanic White (NHW) populations. Here we provide an extensive survey of the proteomic landscape of AD across diverse racial/ethnic groups. METHODS Two cortical regions, from multiple centers, were harmonized by uniform neuropathological diagnosis. Among 998 unique donors, 273 donors self‐identified as African American, 229 as Latino American, and 434 as NHW. RESULTS While amyloid precursor protein and the microtubule‐associated protein tau demonstrated higher abundance in AD brains, no significant race‐related differences were observed. Further proteome‐wide and focused analyses (specific amyloid beta [Aβ] species and the tau domains) supported the absence of racial differences in these AD pathologies within the brain proteome. DISCUSSION Our findings indicate that the racial differences in AD risk and clinical presentation are not underpinned by dramatically divergent patterns in the brain proteome, suggesting that other determinants account for these clinical disparities. Highlights We present a large‐scale proteome (∼10,000 proteins) of DLPFC (998) and STG (244) across AD cases. About 50% of samples were from racially and ethnically diverse brain donors. Key AD proteins (amyloid and tau) correlated with CERAD and Braak stages. No significant race‐related differences in amyloid and tau protein levels were observed in AD brains. AD‐associated protein changes showed a strong correlation between the brain proteomes of African American and White individuals. This dataset advances understanding of ethnoracial‐specific AD pathways and potential therapies.
Recent Developments in Glioblastoma‐On‐A‐Chip for Advanced Drug Screening Applications
Maity, Surjendu , Bhuyan, Tamanna , Kawakita, Satoru , Sharma, Saurabh , Nguyen, Huu Tuan , Najafabadi, Alireza Hassani , Chen, Junjie , Yilgor, Can , Choroomi, Auveen, Torres, Emily, Mecwan, Marvin , Wang, Zhaohui , Quiñones‐Hinojosa, Alfredo , Jucaud, Vadim , Dokmeci, Mehmet R. , Kawakita, Satoru , Sharma, Saurabh , Nguyen, Huu Tuan , Hassani Najafabadi, Alireza , Khorsandi, Danial , Yilgor, Can , Moniz-Garcia, Diogo, Jucaud, Vadim , Dokmeci, Mehmet Remzi , Khademhosseini, Ali , Jewell, Christopher M. , Ermis, Menekşe , Falcone, Natashya , Mandal, Kalpana , Torres, Emily, John, Johnson V. , Akbari, Mohsen , Moniz‐Garcia, Diogo , Khademhosseini, Ali

Mayo Clinic

Small | November 13, 2024 | Volume: 21 | Issue: 1 | Pages: No page available

10.1002/smll.202405511 | PMID 39535474 Get It

Abstract Glioblastoma (GBM) is an aggressive form of cancer, comprising ≈80% of malignant brain tumors. However, there are no effective treatments for GBM due to its heterogeneity and the presence of the blood‐brain barrier (BBB), which restricts the delivery of therapeutics to the brain. Despite in vitro models contributing to the understanding of GBM, conventional 2D models oversimplify the complex tumor microenvironment. Organ‐on‐a‐chip (OoC) models have emerged as promising platforms that recapitulate human tissue physiology, enabling disease modeling, drug screening, and personalized medicine. There is a sudden increase in GBM‐on‐a‐chip models that can significantly advance the knowledge of GBM etiology and revolutionize drug development by reducing animal testing and enhancing translation to the clinic. In this review, an overview of GBM‐on‐a‐chip models and their applications is reported for drug screening and discussed current challenges and potential future directions for GBM‐on‐a‐chip models.
Pemphigoid vegetans presenting as recurrent, non‐healing ulcers on bilateral postauricular sulci
Yang, Eilene, Maniam, Ganesh , Camilleri, Michael , Nguyen, Giang Huong , Maniam, Ganesh Bala, Nguyen, Giang H , Nguyen, Giang H.

Mayo Clinic

JDDG: Journal der Deutschen Dermatologischen Gesellschaft | November 12, 2024 | Volume: 23 | Issue: 1 | Pages: 112-113

10.1111/ddg.15595 | PMID 39530619 Get It

BIOM-16. A TARGETED GENE EXPRESSION BIOMARKER PREDICTS LOW GRADE MENINGIOMA RECURRENCE AND OVERALL SURVIVAL
Raleigh, David R. , Nguyen, Minh, Morshed, Ramin A. , Youngblood, Mark W. , Perlow, Haley K. , Lucas, Calixto‐Hope G. , Patel, Akash J. , Palmer, Joshua D. , McCortney, Kathleen , Horbinski, Craig , Magill, Stephen T. , Chen, William C.

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii22-viii22

10.1093/neuonc/noae165.0089 Get It

Abstract Targeted gene expression profiling improves risk stratification for meningiomas, but the utility of this approach for low grade meningiomas is incompletely understood. To address this, 466 meningiomas that were initially used to validate a 34-gene expression biomarker were combined with 270 previously unpublished samples for an analysis of biomarker performance in newly diagnosed (n=691) or recurrent (n=45) WHO grade 1 meningiomas treated with gross total (GTR) or subtotal resection (STR), and newly diagnosed WHO grade 2 meningiomas treated with GTR. Prediction of local freedom from recurrence (LFFR) or overall survival (OS) was measured using Cox proportional hazards models and the Kaplan-Meier method. The cohort included 736 patients, 69.4% female, with a median age at diagnosis of 58 years. There were 635 WHO grade 1 meningiomas, 498 with GTR and 133 with STR, and 101 WHO grade 2 meningiomas with GTR. The median follow-up was 4.6 years, the local recurrence rate was 12.0% and the rate of death was 8.4%. The biomarker classified 51.5% of meningiomas as intermediate risk and 9.6% as high risk. Combining the biomarker with extent of resection identified 19.7% as unfavorable (intermediate molecular risk with STR or high molecular risk), including 7.4% of newly diagnosed WHO grade 1 meningiomas with GTR. The risk score was prognostic for LFFR overall (hazard ratio per 0.1 increase in risk score 1.89, 95% confidence interval 1.58-2.25) and across WHO grades, extents of resection, and newly diagnosed or recurrent settings. Gene expression risk groups were prognostic for LFFR, with improved outcomes among low molecular risk compared to intermediate molecular risk (Log-rank, p=0.0002) and high molecular risk meningiomas (Log-rank, p<0.0001). These data suggest that a targeted gene expression biomarker can identify low grade meningiomas that are more likely to recur after surgery, possibly changing management for approximately one-fifth of cases.
PATH-08. MOLECULAR DIVERGENCE RATES DIFFER BETWEEN BRAIN METASTASES AND EXTRACRANIAL DISEASE SITES ACROSS PRIMARY TUMOR HISTOLOGIES
Young, Jacob, Malik, Noor Ul Ain , Parney, Ian, Chang, Edward, Berger, Mitchel S. , Theodosopoulos, Philip V. , Hervey‐Jumper, Shawn L. , Vasudevan, Harish N. , Malik, Noor , Malik, Noor , Morshed, Ramin A. , Khela, Harmon Singh , Nguyen, Minh, Goldschmidt, Ezequiel , McDermott, Michael , Malik, Noor, Chang, Edward, Huppert, Laura Ann , Aghi, Manish Kumar

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii179-viii179

10.1093/neuonc/noae165.0707 Get It

Abstract Genomic alterations and molecular subgroups between extracranial disease sites and brain metastases often differ, yet the prevalence and clinical significance of divergent evolution in brain metastases is not fully understood. This study examined genomic alterations and molecular subgroup divergence rates between matched brain metastases and extracranial disease sites. A retrospective, two-center study was conducted on patients who underwent resection of brain metastases between 2014-2022 with clinical and matched genomic data and/or molecular markers available. The overall cohort comprised 256 patients with matched tumors from multiple cancer types, most commonly from breast (n=108, 42.2%), melanoma (n=83, 32.4%), and NSCLC (n=43, 16.8%). Targeted next-generation sequencing of over 500 oncogenes was performed on resected tumors as part of clinical care (n=41 patients with matched specimens). Molecular subgroups for breast, melanoma, and non-small cell lung cancer were also assessed by immunohistochemistry to evaluate rates of molecular subgroup discordance between sites. Subgroup discordance by immunohistochemistry was observed most frequently across breast cancer (22.2%, n=24/108) with loss of the estrogen receptor (ER) and progesterone receptor (PR) and gain of HER2 most frequently observed within brain metastases. Molecular subgroup discordance was rare within melanoma (7.3%, n=6/82) and NSCLC (14.0%, n=6/43) patients. When evaluating oncogenomic alterations from targeted DNA sequencing in 41 patients with matched specimens, 80.5% (33/41) of brain metastases demonstrated a unique oncogene alteration profile compared to an extracranial disease site. Fourteen patients (34.1%) had a gain of at least 1 targetable alteration within a brain metastasis that was not observed in an extracranial disease site. Brain metastases demonstrated high rates of genomic divergence compared to primary and extracranial metastatic disease sites. This data supports obtaining brain metastasis tissue and conducting molecular profiling of this tissue to help select optimal CNS penetrant systemic therapies for each patient.
EPID-09. THE NATURAL HISTORY AND MOLECULAR ARCHITECTURE OF INCIDENTAL MENINGIOMAS
Mirchia, Kanish , Raleigh, David R. , Nguyen, Minh , Chen, William C. , Magill, Stephen T. , Morshed, Ramin A.

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii139-viii139

10.1093/neuonc/noae165.0545 Get It

Abstract The prevalence of asymptomatic, incidental meningiomas is increasing due to greater frequency of brain imaging. This retrospective cohort study of adult patients presenting at a single institution from 1996-2020 integrated clinical data, serial magnetic resonance imaging (MRI) volumetrics, DNA methylation profiling, and targeted gene expression profiling to define the natural history and molecular architecture of incidental meningiomas. Volumetrics were calculated from contrast-enhanced brain MRIs at time of diagnosis compared to serial surveillance MRIs (average 3 MRIs per patient pre-intervention, range: 1-12) DNA methylation groups and gene expression risk scores were defined for 123 samples that underwent resection. Time-to-event analyses were performed for progression-free survival (PFS), symptom-free survival (SFS), and treatment-free survival (TFS). The cohort included 238 meningiomas from 207 patients. Median age at diagnosis was 59 years and 81.5% of patients were female. Median clinical and imaging follow-up were 9.1 and 6.7 years, respectively, during which time 50.8% progressed. Median maximum diameter and volume at diagnosis were 2.20 cm and 4.25 cm3, respectively, and median pre-treatment volumetric growth rate was 19.2% per year. Median pre-treatment PFS and TFS were 3.10 and 1.27 years, respectively, and median SFS and post-treatment PFS were not reached. Cox proportional hazards regression identified maximum diameter at diagnosis as a significant predictor of worse pre-treatment PFS (multivariate HR 1.65 per 1 cm [95% CI 1.19–2.28], p=0.0027) and worse TFS (multivariate HR 1.44 per 1 cm [95% CI 1.17–1.76], p<0.001). Skull base tumors had with worse SFS (multivariate HR 2.48 [95% CI 1.02–6.00], p=0.045). Molecular and histological features among incidental meningiomas that ultimately underwent resection (n=176, 74.0%) were reassuring (89.2% WHO grade 1, 10.2% WHO grade 2). These findings suggest maximum diameter at diagnosis of incidental meningiomas is significantly associated with earlier progression and eventual treatment, and skull base tumors have earlier symptom development.
Abstract 4114716: Concurrent Ethanol Infusion with Pulsed Field Ablation Augments Electroporation of Porcine Atria
Otsuka, Naoto , Tri, Jason , ying, yang , Nguyen, Duy T. , Koya, Taro , Sauer, William H. , Asirvatham, Samuel J.

Mayo Clinic

Circulation | November 11, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4114716 Get It

Background: Pulsed field ablation (PFA) is a promising modality for treatment of cardiac arrhythmias. PFA increases cell permeability, thereby promoting cell apoptosis. Although greater PFA energy may produce larger lesions, it also carries risks of side effects such as arcing, hemolysis, and microbubbles. Chemical ablation using ethanol (EtOH), such as with injection of the Vein of Marshall, has been used to treat atrial myocardium for refractory atrial arrhythmias. Hypothesis: We hypothesize that PFA in the atria can increase EtOH uptake through PFA-generated pores, thereby augmenting ablation efficacy by utilizing the cell permeability effects of PFA. Aim: The aim of this study is to investigate the effects of local EtOH infusion after PFA on lesion size in porcine atria. Methods: The atria of five porcine subjects were ablated in vivo with low PFA power settings (250V, at 20μs for 50 pulses separated by 200 ms) using a focal bipolar irrigated ablation catheter and BTX 830 electroporation generator (Harvard Apparatus). After PFA, 2 ml of 90 % EtOH vs. saline (control) was infused through the catheter tip to the site of ablation. We compared electrogram voltage amplitude reduction and ablation lesion parameters before and after PFA. Results: A total of 14 control lesions and 14 EtOH lesions were analyzed. There was significant difference in voltage reduction between two groups ( Figure 1A-B ). On gross pathology, there were significant differences in ablation lesion maximum surface diameter, lesion depth, and volume between the 2 lesion sets ( Figure 1C ). Conclusion: Concurrent EtOH infusion after PFA enhanced acute efficacy of electroporation in porcine atria. Adjuvant therapy has the potential to improve efficacy without requiring higher energy parameters, thereby reducing PFA risks. Further studies to assess chronic efficacy are warranted.
Nomenclature for human and animal fungal pathogens and diseases: a proposal for standardized terminology
Walsh, Thomas J. , Ahmed, Sarah , Alastruey‐Izquierdo, Ana , Arendrup, Maiken Cavling , Borman, Andrew M. , Colgrove, Robert C. , Cornely, Oliver A. , Filkins, Laura , Groll, Andreas H. , Haase, Gerhard , Hubka, Vít , Kwon-Chung, June , Song, Yinggai , Vilela, Rachel, Vitale, Roxana G. , Wengenack, Nancy L. , de Hoog, Sybren , Walsh, Thomas J , Alastruey-Izquierdo, A , Arendrup, Maiken Cavling , Borman, Andrew , Filkins, Laura , Gené, Josepa , Groll, Andreas H , Hoenigl, Martin , Kidd, Sarah E , Kus, Julianne V , Kwon-Chung, Kyung J , Lockhart, Shawn R. , Meis, Jacques F , Mendoza, Leonel , Nguyen, M Hong , Vitale, Roxana G , Wengenack, Nancy L , White, Lewis , Zhang, Sean X , Cornely, Oliver A , Ahmed, Sarah A , Chen, Wen , Chowdhary, Anuradha , Denning, David W. , Dufresne, Philippe J. , Gangneux, Jean‐Pierre , Guillot, Jacques , Halliday, Catriona , Hawksworth, David L. , Hay, Roderick J. , Hoenigl, Martin , Jagielski, Tomasz , Kandemir, Hazal , Kidd, Sarah , Kus, Julianne V. , Kwon‐Chung, June , Meyer, Wieland , Song, Yinggai , Sorrell, Tania Christine , Stielow, J. Benjamin , Ostrosky‐Zeichner, Luis , Zhang, Sean X.

Mayo Clinic

Journal of Clinical Microbiology | November 11, 2024 | Volume: 62 | Issue: 12 | Pages: No page available

10.1128/jcm.00937-24 | PMID 39526838 Get It

ABSTRACT Medically important pathogenic fungi invade vertebrate tissue and are considered primary when part of their nature life cycle is associated with an animal host and are usually able to infect immunocompetent hosts. Opportunistic fungal pathogens complete their life cycle in environmental habitats or occur as commensals within or on the vertebrate body, but under certain conditions can thrive upon infecting humans. The extent of host damage in opportunistic infections largely depends on the portal and modality of entry as well as on the host’s immune and metabolic status. Diseases caused by primary pathogens and common opportunists, causing the top approximately 80% of fungal diseases [D. W. Denning, Lancet Infect Dis, 24:e428–e438, 2024, https://doi.org/10.1016/S1473-3099(23)00692-8 ], tend to follow a predictive pattern, while those by occasional opportunists are more variable. For this reason, it is recommended that diseases caused by primary pathogens and the common opportunists are named after the etiologic agent, for example, histoplasmosis and aspergillosis, while this should not be done for occasional opportunists that should be named as [causative fungus] [clinical syndrome], for example, Alternaria alternata cutaneous infection. The addition of a descriptor that identifies the location or clinical type of infection is required, as the general name alone may cover widely different clinical syndromes, for example, “rhinocerebral mucormycosis.” A list of major recommended human and animal disease entities (nomenclature) is provided in alignment with their causative agents. Fungal disease names may encompass several genera of etiologic agents, consequently being less susceptible to taxonomic changes of the causative species, for example, mucormycosis covers numerous mucormycetous molds.
Identifying important and feasible primary care structures and processes in the US healthcare system: a modified Delphi study
Albert, Stephanie L. , Kwok, Lorraine , Shelley, Donna , Paul, Maggie M, Blecker, Saul , Nguyen, Ann , Harel, Daphna , Cohen, Deborah J. , Berry, Carolyn A. , Paul, Maggie M, Cleland, Charles M. , Weiner, Bryan Jeffrey , Damschroder, Laura J.

Mayo Clinic

BMJ Open | November 9, 2024 | Volume: 14 | Issue: 11 | Pages: e082989

10.1136/bmjopen-2023-082989 | PMID 39521461 Get It

Objective To identify primary care structures and processes that have the highest and lowest impact on chronic disease management and screening and prevention outcomes as well as to assess the feasibility of implementing these structures and processes into practice. Design A two-round Delphi study was conducted to establish consensus on the impact and feasibility of 258 primary care structures and processes. Participants 29 primary care providers, health system leaders and health services researchers in the USA. Outcomes Primary outcomes were (1) consensus on the impact of each structure and process on chronic disease management and screening and prevention outcomes, separately and (2) consensus on feasibility of implementation by primary care practices. Results Consensus on high impact and feasibility of implementation was reached on four items for chronic disease management: ‘Providers use motivational interviewing to help patients set goals’, ‘Practice has designated staff to manage patient panel’, ‘Practice has onsite providers or staff that speak the most dominant, non-English language spoken by patients’ and ‘Practice includes mental health providers and/or behavioural health specialists in care team’ and seven items for screening and prevention: ‘Practice utilizes standing protocols and orders’, ‘Practice generates reports to alert clinicians to missed targets and to identify gaps in care, such as overdue visits, needed vaccinations, screenings or other preventive services’, ‘Practice has designated staff to manage patient panel’, ‘Practice sets performance goals and uses benchmarking to track quality of care’, ‘Practice uses performance feedback to identify practice-specific areas of improvement’, ‘Practice builds quality improvement activities into practice operations’ and ‘Pre-visit planning data are reviewed during daily huddles’. Only ‘Practice has designated staff to manage patient panel’ appeared on both lists. Conclusion Findings suggest that practices need to focus on implementing mostly distinct, rather than common, structures and processes to optimise chronic disease and preventive care.